Zevra 10-Q: Q3 Net Income $19.2M, Nine-Month Net Income $65.9M, $270.9M Cash
ZVRA sits 31% above its 52-week low of $8.01.
Summary
Zevra reported Q3 2026 net income of $19.2 million on $37.8 million of revenue and held $270.9 million in cash and investments with no debt. Its European arimoclomol application remains in re-examination after a negative CHMP opinion.
Key Events · Earnings and Guidance · ZVRA
-
Q3 Revenue $37.8M, Net Income $19.2M
Third-quarter revenue rose to $37.8 million from $26.1 million a year earlier, with MIPLYFFA sales of $34.0 million versus $22.4 million. Net income was $19.2 million, or $0.26 per diluted share.
-
Nine-Month Net Income $65.9M
Nine-month net income of $65.9 million included a $43.3 million net gain on the Commave Settlement Agreement, under which Commave paid $50.0 million for the SDX portfolio assets and the AZSTARYS license was terminated.
-
Cash $270.9M, Debt Fully Repaid
Cash, cash equivalents and investments totaled $270.9 million at September 30, 2026, and the $63.1 million term loan was repaid in full on March 12, 2026, leaving no long-term debt. Management says this funds planned requirements for at least the next twelve months.
-
European Arimoclomol Opinion Negative
The CHMP adopted a negative opinion on the arimoclomol MAA in July 2026; Zevra has requested a re-examination. A $4.0 million regulatory milestone to XOMA is tied to E.U. approval.
Analysis · ZVRA · Life Sciences
The headline numbers show a sharp swing: $19.2 million of net income on $37.8 million of revenue in the third quarter, and $65.9 million of net income for the first nine months of 2026, versus a prior-year loss. MIPLYFFA sales drove the turn, aided by a $43.3 million gain on the Commave settlement. Yet the balance sheet is the real story. Cash and investments stood at $270.9 million with no debt after the March repayment of the $63.1 million term loan, which management says funds planned requirements for at least the next twelve months. Against that, the European arimoclomol application took a negative CHMP opinion in July 2026 and is in re-examination, and OLPRUVA is being scaled back while strategic alternatives are weighed. The growth case now rests almost entirely on MIPLYFFA in the U.S.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ZVRA was trading at $10.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $609.3M. The 52-week trading range was $8.01 to $15.04. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.